Predicting success in the endoscopic management of pediatric vesicoureteral reflux.
Vesicoureteral reflux is a common cause of pediatric morbidity. Though traditionally managed using a limited number of therapeutic modalities, the last decade has witnessed countless surgical innovations for treating reflux. A major force behind this innovation is the increasing use of endoscopic injection, which currently constitutes nearly half of all anti-reflux procedures performed in the United States. However, published success rates for injection vary dramatically. Despite a relative lack of comparative data, multiple studies have attempted to define the most important prognostic factors for injection success. This article is an attempt to summarize these findings.
Routh
Jonathan C
JC
Department of Urology, Children's Hospital Boston, Boston, Massachusetts, USA.
Reinberg
Yuri
Y
D003558:Cystoscopy; D003911:Dextrans / Q000008:administration & dosage; D006801:Humans; D006820:Hyaluronic Acid / Q000008:administration & dosage; D011379:Prognosis; D012074:Remission Induction; D014718:Vesico-Ureteral Reflux / Q000628:therapy*
D003911:Dextrans; C487487:dextranomer-hyaluronic acid copolymer; D006820:Hyaluronic Acid